



December 2024



\$25,000,000

Private Placement

Exclusive Placement Agent



For more information please contact :

Investment Banking

David Lee
Senior Managing Director
Direct: +1 (929) 625-0988
dlee@dboralcapital.com

Gaurav Verma
Co-Head, Investment Banking
Direct: +1 (929) 528-0912
gverma@dboralcapital.com

Stephanie Hu
Co-Head, Investment Banking
Direct: +1 (929) 586-0272
shu@dboralcapital.com

Equity Capital Markets

Philip Wiederlight
Chief Operating Officer
Direct: +1 (929) 625-1539
pwiederlight@dboralcapital.com

Mark Iorio
Director, Equity Capital Markets
Direct: +1 (929) 528-0913
miorio@dboralcapital.com

D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its \$25.0 Million Financing

Transaction Information

HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN LTD. ("Yorkville"), an investment fund managed by Yorkville Advisors Global, LP. The agreement allows FibroBiologics, subject to customary conditions, to sell up to \$25 million in the aggregate of its common stock to Yorkville over the course of two years.

Yorkville agreed to advance to FibroBiologics the first \$15 million available under the SEPA in three equal tranches to be evidenced by convertible promissory notes. The first tranche in the amount of \$5 million was funded upon entry into the SEPA. Subject to the satisfaction of certain conditions, the second tranche of \$5 million will fund after the filing of a registration statement covering the resale of the shares issuable to Yorkville under the promissory notes, and the third tranche of \$5 million will fund following the effectiveness of the registration statement and receipt of shareholder approval in satisfaction of Nasdaq rules. FibroBiologics can sell an additional \$10 million of its common stock to Yorkville, subject to Yorkville's consent and other conditions, while the convertible promissory notes remain outstanding.

"The initial advances from this financing will allow us to complete our first-in-human trial for diabetic foot ulcers as well as IND-enabling studies for our psoriasis program," said Pete O'Heeron, Founder & Chief Executive Officer of FibroBiologics. "We expect to further develop our human longevity, multiple sclerosis, and cancer indications by utilizing the remaining capital available under the SEPA."

About FibroBiologics, Inc.

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.

About D. Boral Capital

D. Boral Capital LLC is an investment bank headquartered in New York which provides advisory and financing solutions to middle market and emerging growth companies. The Company has a proven track record of offering strategic guidance to clients across the globe in any sector, with access to capital from the USA, Asia, Europe, UAE, and Latin America.

D. Boral Capital is a leader on Wall Street, having aggregated over \$23 billion in capital across approximately 300 transactions through various product types.

